Advertisement
Screener

SCIENTURE HOLDINGS, INC. (SCNX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

2.8 / 5 stars · 68/120 Roast Me

SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 0.25% for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-10-25.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2021-10-25

  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2021-03-31 was 0.25%, a 99.89% decline year-over-year.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2020-03-31 was 226.00%.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 0.25%, a 99.90% decline from fiscal 2019.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2019 was 250.00%, a 5.66% decline from fiscal 2018.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2018 was 265.00%, a 32.50% increase from fiscal 2017.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2017 was 200.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month
2021-09-300.25%
10-Q · filed 2021-10-25
2021-06-300.25%
10-Q · filed 2021-07-26
2021-03-310.25%
10-Q · filed 2021-04-26
2020-12-310.25%
10-K · filed 2021-03-29
2020-09-30236.00%
10-Q · filed 2020-10-26
2020-06-30236.00%
10-Q · filed 2020-07-27
2020-03-31226.00%
10-Q · filed 2020-05-04
2019-12-31250.00%
10-K · filed 2020-03-30
2019-09-30250.00%
10-Q · filed 2019-10-28
2019-06-30250.00%
10-Q · filed 2019-07-26
2018-12-31265.00%
10-K · filed 2020-03-30
2017-12-31200.00%
10-K · filed 2019-03-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
BIOVIE INC. (BIVI)United States$0.012B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33